Warm Autoimmune Hemolytic Anemia (WAIHA) - Epidemiology Forecast - 2032

DelveInsight’s "Warm Autoimmune Hemolytic Anemia (wAIHA) —2032" report delivers an in-depth understanding of the Warm Autoimmune Hemolytic Anemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Warm Autoimmune Hemolytic Anemia Disease Understanding
Warm Autoimmune Hemolytic Anemia (wAIHA) is one of the most prevalent psychiatric disorders and has been projected by the World Health Organisation to be the leading cause of disease burden in high-income countries by 2032. Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation. Autoantibodies are produced by both tissue and circulating self-reactive B lymphocytes, following cooperation with T helper lymphocytes.
wAIHA is the most common type of autoimmune hemolytic anemia, comprising ∼70–80% of all adult cases and ∼50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology, while the rest is termed as secondary to lymphoproliferative syndromes, malignant diseases including chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and solid tumors.
Currently, there are no approved therapies for the management of wAIHA, with only one-third of the patients maintaining sustained disease control once steroids are discontinued.
As per DelveInsight’s estimation, the future of wAIHA treatment is continuing to trend toward complement inhibitors, Syk kinase inhibitors, and FcRn receptor antagonist MAb. If these therapies are ultimately successfully commercialized, they have the potential to transform the current standard of care for wAIHA patients.

Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology

The Warm Autoimmune Hemolytic Anemia (wAIHA) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Warm Autoimmune Hemolytic Anemia epidemiology segmented as Total Prevalent Cases of Autoimmune Hemolytic Anemia, Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia, Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia, and Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia. The report includes the prevalent scenario of Warm Autoimmune Hemolytic Anemia in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Warm Autoimmune Hemolytic Anemia Epidemiology

The epidemiology segment also provides the Warm Autoimmune Hemolytic Anemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Warm Autoimmune Hemolytic Anemia associated in 7MM countries was estimated to be 116,507 cases in 2022 and expected to increase at a CAGR of 0.38% for the study period, i.e., 2019–2032.
As per the estimates, United States has the highest prevalent population of Warm Autoimmune Hemolytic Anemia in 7MM.

Among the EU5 countries, Germany had the highest prevalent population of Warm Autoimmune Hemolytic Anemia. On the other hand Spain had the lowest incident population. In 7MM, Spain had the lowest number of cases, 6,956 cases in 2022.

Scope of the Report
Warm Autoimmune Hemolytic Anemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
Warm Autoimmune Hemolytic Anemia Epidemiology Report and Model provides an overview of the risk factors and global trends of Warm Autoimmune Hemolytic Anemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Warm Autoimmune Hemolytic Anemia in the seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Warm Autoimmune Hemolytic Anemia
The report provides the segmentation of the Warm Autoimmune Hemolytic Anemia epidemiology by incident cases of Warm Autoimmune Hemolytic Anemia in 7MM
The report provides the segmentation of the Warm Autoimmune Hemolytic Anemia epidemiology by Total Prevalent Cases of Autoimmune Hemolytic Anemia, Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia, Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia, and Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia

Report Highlights
11-year Forecast of Warm Autoimmune Hemolytic Anemia epidemiology
7MM Coverage
Total Prevalent Cases of Autoimmune Hemolytic Anemia
Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia
Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia
Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM concerning the patient population about Warm Autoimmune Hemolytic Anemia?
What are the Key Findings of Warm Autoimmune Hemolytic Anemia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021–2032)?
What would be the total number of patients with Warm Autoimmune Hemolytic Anemia across the 7MM during the forecast period (2021–2032)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021–2032)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021–2032)?
What are the disease risk, burden, and unmet needs of Warm Autoimmune Hemolytic Anemia?
What are the currently available treatments for Warm Autoimmune Hemolytic Anemia?

Reasons to buy

The Warm Autoimmune Hemolytic Anemia Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Warm Autoimmune Hemolytic Anemia market
Quantify patient populations in the global Warm Autoimmune Hemolytic Anemia market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Warm Autoimmune Hemolytic Anemia therapeutics in each of the markets covered
Understand the magnitude of Warm Autoimmune Hemolytic Anemia population by its incident cases
Understand the magnitude of Warm Autoimmune Hemolytic Anemia population by its clinical manifestation specific cases
The Warm Autoimmune Hemolytic Anemia epidemiology report and model was written and developed by Masters and PhD level epidemiologists
The Warm Autoimmune Hemolytic Anemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019–2032